Depletion of regulatory T cells (Tregs), for instance, via low-dose cyclophosphamide, has been shown to improve anti-tumor responses in preclinical GBM models by reducing IL-10 production and enhancing effector T cell function [78,79]. This evidence concerns the gene IL10 and neoplasm.